<DOC>
	<DOCNO>NCT00002200</DOCNO>
	<brief_summary>The purpose study see safe effective give 1592U89 HIV-positive adult . This study also examine influence previous anti-HIV treatment effectiveness 1592U89 .</brief_summary>
	<brief_title>A Study 1592U89 HIV-Infected Adults</brief_title>
	<detailed_description>Patients receive open-label 1592U89 administer orally combination least one antiretroviral agent patient previously receive .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Erythropoietin , GCSF GMCSF . Patients must : CD4+ cell count &lt; 100 cells/mm3 . HIV1 RNA &gt; 30,000 copies/ml . Signed , inform consent parent legal guardian patient 18 year age . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Renal failure require dialysis . Hepatic failure evident grade 3/4 hyperbilirubinemia AST 5 time upper limit normal . Documented hypersensitivity 1592U89 . Serious medical condition , diabetes , congestive heart failure , cardiomyopathy , cardiac dysfunction , would compromise safety patient . Participation ability participate enrol study 1592U89 . Required : At least 2 nucleoside reverse transcriptase inhibitor ( NRTI ) one protease inhibitor ( intolerance one protease inhibitor one NRTI due try least 2 different regimen least one protease inhibitor ) . Alcohol illicit drug use may interfere patient 's compliance .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 1998</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>CD4 Lymphocyte Count</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>abacavir</keyword>
</DOC>